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Purpose: Sputum analysis is important in COPD exacerbation management. We determined
whether application of stringent quality control criteria for sputum samples had an impact
on culture results.
Methods: We analyzed sputum samples of 108 patients during stable COPD and during exacer-
bations. To all samples quality control standards and culture interpretation rules according to
the American Society of Microbiologists (ASM) were applied.
Results: In sputum exacerbation samples considered appropriate according to ASM quality stan-
dards, criteria for infection (40%)weremetmore often compared to inappropriate samples (13%)
(p< 0.001). The same pattern was observed when applying these rules to sputum samples ob-
tained during stable disease, (50% vs. 18%, p< 0.001). Therewas no difference in the percentage
of infectious cultures obtained during the stable state and exacerbations.
Conclusions: Applying stringent quality control criteria to sputum samples can have a profound
effect on the labeling of sputum samples as infectious, and therefore on clinical decisionmaking.
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Chronic obstructive pulmonary disease (COPD) is a major
cause of chronic morbidity and mortality throughout the
world. Morbidity and mortality among patients with COPD
are for a large part related to acute exacerbations of COPD,
which occur on average 1e3 times a year.1 COPD exacer-
bations are heterogeneous events that are thought to be
caused by complex interactions between the host, respi-
ratory viruses, airway bacteria, and environmental pollu-
tion, leading to an increase in the inflammatory burden.2
Sputum analysis is an important clinical tool in the
management of COPD, especially in COPD exacerbations,
for decisions to prescribe antibiotics. The most common
test in exacerbations is taking a sputum sample for culture
to determine the presence, abundance, and resistance
pattern of bacteria. Multiple studies show that there is
a variety of microorganisms present in cultures of patients
with acute exacerbations of COPD.3,4The presence of
microorganisms however does not directly signify that
these organisms are the causative agent of an infection;
patients can just be colonized.
In addition to culturing sputum, other clinical features
and markers have been used to determine the nature of
COPD exacerbations. A marker that has been commonly
used since the study of Anthonisen et al. in 1987, is sputum
purulence,5 which is seen as an indirect marker for the
presence of bacteria. Also Stockley et al. used sputum color
(or purulence) as the primary parameter to decide whether
or not to start antibiotic treatment.6 Additionally, the
concentration of inflammatory markers and cell types are
also commonly analyzed in sputum samples. Sethi and
colleagues showed that neutrophilic airway inflammation
and systemic inflammation are more intense with well-
defined bacterial exacerbations than with nonbacterial
exacerbations.7 Other parameters that can indicate the
presence of a bacterial infection are C-reactive protein,
TNF alpha and interleukins (IL-6, IL-8).8e10
All these studies show that sputum analysis is an
important clinical tool in the management of COPD.
When collecting sputum samples, there is a high vari-
ability in the quality of the samples obtained. In 1975
Murray et al. designed criteria for the quality of sputum.
Specimens were categorized according to the number of
leukocytes and squamous epithelial cells observed micro-
scopically in a Gram-stained smear.11 When the number of
squamous epithelial cells was far greater than the number
of leucocytes in the sputum, they assumed that this spec-
imen originated from the upper airways and therefore
should not be further analyzed. The American Society of
Microbiologists (ASM) also advocates quality control stan-
dards and culture interpretation rules.12 Although these
quality statements have now existed for many years, pub-
lished studies involving sputum analysis often do not report
on the quality control standards they used for sputum
samples and whether sputum samples of inadequate quality
were removed from further analyses. We hypothesize that
using sputum samples of inadequate quality can suggest an
active infection in the lower airways while the sputum
sample originates from the pharynx and therefore this
influences the interpretation of culture results and clinicaldecision making. Therefore, we performed a study on sputa
of COPD patients in the stable state and during acute
exacerbations to study the differences between adequate
and inadequate sputum samples as based on the ASM




To be eligible for the study the patients had to meet the
following criteria: (1) a clinical diagnosis of COPD, as
defined by American Thoracic Society criteria 13; (2) no
history of asthma; (3) no exacerbation in the month prior to
enrolment; (4) current or former smoker; (5) age between
40e75 years; (6) baseline pre-bronchodilator forced expi-
ratory volume in one second (FEV1) 25e85% of predicted;
(7) pre-bronchodilator ratio FEV1 to inspiratory vital
capacity (IVC) 60% or less; (8) reversibility of FEV1 post
inhalation of 80 mg of ipratropium bromide via metered
dose inhalator with an aerochamber 12% predicted 14; (9)
total lung capacity (TLC) greater than the TLC predicted
minus 1.64 SD; (10) no maintenance treatment of oral
steroids or antibiotics; (11) no medical condition with low
survival or serious psychiatric morbidity (e.g. cardiac
insufficiency, alcoholism); and (12) absence of any other
active lung disease (e.g. sarcoidosis).
The use of medication such as nasal corticosteroids,
theophyllines, chronic use of acetylcysteine and all other
bronchodilators was allowed.
The hospital’s medical ethical committee approved this
study. All patients provided written informed consent.
Study design
This study was performed on data of the COPE study.15,16
Patients were instructed to contact the study personnel
any time they experienced a worsening of their respiratory
symptoms. They were subsequently invited to visit the
outpatient department within 12 h for lung function
measurements, sputum collection and consultation by one
of the study physicians. Exacerbations were defined as
worsening of respiratory symptoms that required treatment
with a short course of oral corticosteroids or antibiotics as
judged by the study physician. The stable state was defined
as a period of 4 weeks with no change in respiratory
symptoms beyond day-to-day variations.
Outcome measures
Sputum samples were taken in the stable state and during
acute exacerbation. During the collection of the stable
state sputa all patients were on inhaled corticosteroids
(ICS) according to the COPE protocol. The samples obtained
during exacerbation were taken both from patients on ICS
and patients on placebo in line with the design of the COPE
study.16 Sputum samples were collected in sterile vials and
processed in the laboratory within 4 hours. Sputa were
homogenized by incubation at 37 C for 15 min with an
equal volume of 0.1% dithiothreitol.
Table 1 Baseline characteristics. Data are presented as
mean (SD) or number (%).
(NZ 108)




FEV1 in L 1.68 (0.57)
FEV1% predicted 57.4 (14.5)
IVC in L 3.8 (0.87)
FEV1/IVC % 44.4 (10.8)
Total number of sputum
samples during exacerbation
139
Total number of sputum
samples during the stable state
122
Sputum quality and clinical decisions 373In line with the ASM criteria, sputum samples with less
than 105 mL1 squamous epithelial cells were considered
representative bronchial samples and were defined as
adequate samples. All other samples were classified as
inadequate.12,17 A Gram stain and semi-quantitative
culture were performed for all collected sputum samples,
irrespective of whether the sample was defined as
adequate. Bacterial infection was defined per ASM criteria
as the presence of potential pathogenic microorganisms
(PPM) in pure culture or as the presence of one or more PPM
in excess (one log or more) to normal microbiological flora
in sputum. Criteria for bacterial colonization were also
defined also by ASM criteria as the presence of PPM in
culture in equal amount or less compared to normal
microbiologic flora in sputum.12,17
In all sputum samples IL-6, IL-8 and TNF-a concentra-
tions were quantified using PeliKine Compact human
sandwich ELISA kits (Sanquin, CLB, Amsterdam the
Netherlands). These tests were standard tests with an
inter- and intra-test variability of a set of selected refer-
ence samples, which never exceeds 10%. To process the
sputum samples DTT was not used. The sputum was
homogenized and analyzed without adding any agent. MPO
enzymatic activity in sputum was determined by colori-
metric change in absorbance during a reaction with O-dia-
nisidine dihydrochloride (Sigma-Aldrichª). Spirometry was
performed according to standardized guidelines.18 FEV1 and
IVC were measured until three reproducible recordings (less
than 5% difference) were obtained. The highest values were
used for analyses.
Statistical analyses
Baseline characteristics are reported as mean SD or as
numbers with corresponding percentages for categorical or
dichotomous variables. Not normally distributed variables
are reported as median with corresponding range.
To identify whether there were differences between
sputum of adequate and inadequate samples, Chi-square or
Fisher exact tests were performed as appropriate.
Results
Sputum samples of 108 patients were used for analyses. A
total of 261 sputum samples were collected, of which 122Table 2 Number of sputa that met criteria for bacterial infec
during COPD exacerbation and number of sputa that met criteria
samples obtained in the stable state.
Bacterial
Exacerbation
Adequate sputum quality 32 (40.5%
Inadequate sputum quality 8 (13.3%
p-Value <0.001
Stable state
Adequate sputum quality 28 (50.0%
Inadequate sputum quality 12 (18.2%
p-Value <0.001were in the stable state and 139 during acute exacerbation.
Baseline characteristics of all patients are shown in Table 1.
Sixty of the 139 (43%) samples collected during exacer-
bations were classified as inadequate (Table 2). In sputum
samples of adequate quality the probability of meeting the
criteria for bacterial infection was increased threefold (CI
95%: 1.58e3.05; p< 0.001) compared to inadequate
sputum samples. Without the application of the quality
criteria standard the overall percentage of sputa meeting
the criteria for bacterial infection was 29%, compared to
40.5% in sputum samples of adequate quality (Table 2).
Table 2 also shows the number of sputa obtained in the
stable state, again divided into adequate and inadequate
sputum samples. Sixty-six of the 122 (54%) collected
samples were classified as inadequate. In adequate sputum
samples the probability of meeting criteria for bacterial
infection was increased 2.8-fold (CI 95%: 1.49e2.88;
p< 0.001) compared to inadequate sputum samples.
Without the application of the standard ASM quality criteria
the overall percentage of sputa meeting the criteria for
bacterial infection was 36%, compared to 50% in sputum
samples of adequate quality.
In sputa obtained during the stable state 1.25 times (CI
95%: 1.01e1.56; pZ 0.04) more sputa were classified as
inadequate compared to sputa collected during exacerba-
tion. Furthermore, the adequate sputa samples obtained
during the stable state and during exacerbations showed notion in adequate and inadequate sputum samples obtained
for bacterial infection in adequate and inadequate sputum







Table 3 Concentration of inflammatory markers in adequate and inadequate sputum samples obtained during COPD exac-
erbation. Concentrations are displayed as median (25e75 percentiles).
TNF-a (pg/ml) IL-6 (pg/ml) IL-8 (pg/ml)a MPO (extinction)
Bacterial infection
Adequate sputum 600 (179e1001b) 7 (1.3e32) 241 (150e241a) 1.3 (0.7e2.1)
Inadequate sputum 175 (61e453) 8.9 (0.6e58.1) 200 (16e241a) 1.3 (0.5e1.8)
p-Value 0.044 0.753 0.130 0.787
No bacterial infection
Adequate sputum 39 (9e725) 34 (8e100) 50 (15e241a) 1.0 (0.1e2.1)
Inadequate sputum 13 (0.0e115) 17 (4.6e46.5) 36 (4.4e70) 0.3 (0.1e1.0)
p-Value 0.010 0.100 0.052 0.067
a All IL-8 concentrations >240 were labeled 241.
b All TNF-a concentrations >1000 pg/ml were labeled 1001.
374 M.C. Telgen et al.difference in the number of sputa that met the criteria for
bacterial infection (pZ 0.2).
The concentration of TNF-a in sputum samples obtained
during COPD exacerbations was significantly higher in
adequate samples than in inadequate sputum samples,
both in sputum samples that met criteria for bacterial
infection and in those that did not (Table 3). No significant
differences were found in other inflammatory markers (IL-
6, IL-8, and MPO).
Table 4 shows that in sputum samples obtained in the
stable state the concentration of IL-8 was significantly
higher in adequate samples than in inadequate sputum
samples in sputum samples that met criteria for bacterial
infection. In sputum samples that did not meet criteria for
bacterial infection, adequate sputum samples showed
significantly higher concentrations of TNF-a and IL-6 than
inadequate samples.
When we compared the concentration of inflammatory
markers in adequate samples obtained in stables state and
during COPD exacerbation, we observed no significant
differences in the concentrations of TNF-a, IL-6, IL-8, and
MPO between these samples.Discussion
In sputum samples obtained during acute exacerbations of
COPD, considered appropriate according to the ASM quality
standards, criteria for bacterial infection (40%) were metTable 4 Concentration of inflammatory markers in adequate a
Concentrations are displayed as median (25e75 percentiles).
TNF-a (pg/ml)b IL-6 (pg/m
Bacterial infection
Adequate sputum 715 (220e1001b) 18.5 (1.2e
Inadequate sputum 1001 (225e1001b) 17.5 (3.1e
p-Value 0.588 0.376
No bacterial infection
Adequate sputum 120 (4.5e792.5) 78.0 (15.3
Inadequate sputum 10.3 (0.0e99.8) 19 (1.7e
p-Value 0.035 0.020
a All IL-8 concentrations >240 were labeled 241.
b All TNF-a concentrations >1000 pg/ml were labeled 1001.more often as compared to inappropriate sputum samples
(13%). Moreover, when applying these well-defined ASM
criteria to sputum samples obtained during stable disease
exactly the same pattern of more infections in adequate
samples was observed (50% infections vs. 18%). Applying
stringent quality control criteria to sputum samples can
therefore have a profound effect on clinical decision-
making.
This study showed that both during exacerbations and in
the stable state a large number, respectively, 54% and 43% of
the sputum samples were inadequate. Roche et al. also
observed a low percentage of sputum samples from COPD
patients (20.5%) that satisfied their quality criteria (i.e.>25
polymorphonuclear leukocytes and <10 epithelial cells per
field at 100).19 These criteria are equal to the Murray
criteria.11 Although the study of Roche et al. was performed
in COPD patients admitted to the hospital for an exacerba-
tion and they used quality criteria that differed from the ASM
criteria, both studies show that collection of inadequate
sputum samples is a very common feature in COPD patients.
Our finding of so many inadequate samples is important
because we observed that the criteria for infections were
met considerably more frequently in adequate samples
than in inadequate samples, both for samples collected
during exacerbations and during the stable state. Since
potential pathogenic microorganisms (PPM) causing bacte-
rial infections have been suggested to be located in the
lower airways3 it is not surprising that samples from the
upper airways, i.e. inadequate samples, meet criteria fornd inadequate sputum samples obtained in the stable state.
l) IL-8 (pg/ml)a MPO (extinction)
78.3) 241 (241e241a) 1.5 (0.8e2.2)
77.5) 122.5 (65.8e241a) 1.7 (0.2e2.9)
0.009 0.651
e388.3) 90 (9e241a) 0.6 (0.2e2,0)
50) 22 (3.5e241a) 0.2 (0.1e1.1)
0.068 0.156
Sputum quality and clinical decisions 375bacterial infection less often. Furthermore, dilution of
sputum with saliva can cause lower concentrations of PPM
in the obtained samples and therefore failure to meet
criteria for bacterial infection. As mentioned earlier, our
study showed a higher percentage of inadequate samples
collected during the stable state compared to samples
collected during exacerbation. A possible explanation for
this might be the difficulty of coughing up of spontaneous
sputum in the stable state. A solution would be the use of
sputum induction. Sputum induction has been proven to be
safe in the stable state, even in patients with moderate to
severe COPD20 and recently it has also been shown to be
safe in COPD exacerbations in patients with mild to
moderate COPD.21
Many contradictory results have been published on
sputum inflammatory markers in COPD.10,22e25 In our study
we also looked at sputum markers. Before discussing our
results we however should mention that half of our patients
received ICS. Since the literature is not consistent about
the effect of ICS26,27 on inflammatory markers associated
with neutrophils, we combined the data of the groups with
and without ICS in the analyses presented here.
We found that levels of TNF-a differed between
adequate and inadequate samples obtained during exac-
erbation. In samples obtained in the stable state that met
criteria for bacterial infection, the concentration of IL-8
differed between adequate and inadequate samples. In
samples obtained in the stable state that did not meet
criteria for bacterial infection, the concentrations of TNF-
a and IL-6 differed between adequate and inadequate
samples. A possible explanation for the variability in
observed levels of inflammatory markers and associations
with various outcomes in the literature could therefore be
due to different criteria used for sputum quality.
A remarkable finding of this study was that not only
a high percentage of samples collected during exacerbation
met the criteria for bacterial infection, but also an almost
equal percentage of samples collected during the stable
state met the same criteria for bacterial infection. Addi-
tionally the concentrations of the inflammatory markers
TNF-a, IL-6, IL-8 and MPO also did not differ between
adequate samples obtained in the stable state and during
exacerbation. This raises the question whether the criteria
for bacterial infection are adequate to distinguish bacterial
infection during exacerbation from bacterial colonization
either during exacerbation or during the stable state. We
know from literature that a large number of COPD patients
are colonized, varying from 33% to 100%.28 As in our
investigation, Sethi et al. also did not find an increase in
bacterial load during exacerbations in their longitudinal
cohort of COPD patients.29 This raises the question whether
or not infection with bacteria caused an exacerbation or
this was due to, e.g. a viral infection. Finally, it is possible
that the setting of our study (out-patients with COPD who
were taken off inhaled steroids) might have favoured an
increase in non-infectious exacerbations relative to for
instance studies in patients hospitalised for a COPD
exacerbation.
In conclusion, applying stringent quality control criteria
to sputum samples can have a profound effect on the
percentage of positive sputum cultures and by inference on
clinical decision-making.This is probably also true for the application and
analysis of other biomarkers in sputum samples. It is
therefore necessary that quality criteria are used and
published in study reports on sputum outcomes in COPD.
Furthermore, more longitudinal research is needed on the
change in bacterial load from the stable state to
exacerbations.Acknowledgements
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